EUSA Pharma
Financials
Estimates*
EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|---|
Revenues | 21.3m | 38.0m | 63.2m | 81.6m | 168m | 135m | 146m |
% growth | 16 % | 79 % | 66 % | 29 % | 106 % | (20 %) | 8 % |
EBITDA | <1m | 2.0m | 50.0m | (1.0m) | 30.0m | 32.8m | 17.0m |
% EBITDA margin | - | 5 % | 79 % | (1 %) | 18 % | 24 % | 12 % |
Profit | (5.4m) | (7.5m) | 30.1m | (26.4m) | 9.2m | 6.0m | (4.4m) |
% profit margin | (26 %) | (20 %) | 48 % | (32 %) | 5 % | 4 % | (3 %) |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$14.0m | Early VC | ||
$12.5m | Early VC | ||
N/A | $18.6m | Late VC | |
N/A | $9.1m | Early VC | |
N/A | N/A | - | |
N/A | - | ||
$680m | Acquisition | ||
Total Funding | €49.3m |
Recent News about EUSA Pharma
EditEUSA Pharma is a dynamic, global specialty pharmaceutical company focused on developing and commercializing innovative medicines for oncology and rare diseases. The company serves patients worldwide, aiming to make a meaningful difference in their lives by providing access to life-changing treatments. EUSA Pharma operates in the pharmaceutical market, targeting both healthcare professionals and patients who require specialized therapies. The business model revolves around research and development, clinical trials, regulatory approvals, and the commercialization of its products. Revenue is generated through the sale of its pharmaceutical products, which are distributed globally. The company is committed to expanding its product portfolio and reaching more patients in need.
Keywords: oncology, rare diseases, innovative medicines, global distribution, clinical trials, regulatory approvals, patient-focused, specialty pharmaceuticals, healthcare professionals, life-changing treatments.